Julie Lang, MD
Surgical Oncology · Cleveland, OHNPI 1023191517
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $1,875 of the $2,913 with a category attached, or 64.4%. Novartis accounts for 68.9% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2024 at $2,300 and has fallen 90.7% since, to $213 in 2025.
Across 11 payments — averaging $264.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$2K
- AbbVie$227
- Molli Surgical (US) Inc$202
- Merck$180
- Hologic Sales And Service, LLC$123
- Myriad Genetic Laboratories, Inc.$105
- plus $68 from 1 others
Across 7 payments — averaging $34,428 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$241K
What the payments were for
- Consulting fees$1,87564%
- Food & beverage$1,03836%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 3 | $2,008 |
| AbbVie | 2 | $227 |
| Molli Surgical (US) Inc | 1 | $202 |
| Merck | 2 | $180 |
| Hologic Sales And Service, LLC | 1 | $123 |
| Myriad Genetic Laboratories, Inc. | 1 | $105 |
| Genentech USA, Inc. | 1 | $68 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,913 in reported general payments places this provider in the 70th percentile of 69 surgical oncology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cephalexin | 14 | $101 |
Paid to pharmacies, not to this prescriber.
Other surgical oncology in Cleveland
- John AmmoriCleveland$6K
- Luke RothermelCleveland$4K
- Samer NaffoujeCleveland$4K
- Jordan WinterCleveland$2K
- Richard HoehnCleveland$1K
- Benjamin LiCleveland$400
- Joseph SkitzkiCleveland$287
- Stacy KowalskyCleveland$255
- Regina Matar-UjvaryCleveland$253
- Tasadooq HussainCleveland$219
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.